Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy

Journal of Nuclear Medicine

Volumn 50, Issue 1, 2009, Pages 116-122

  Morrison, Matthew S ^a   Ricketts, Sally Ann ^b   Barnett, Jon ^a   Cuthbertson, Alan ^c   Tessier, Jean ^b   Wedge, Stephen R ^b  

^a GE HEALTHCARE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c GE HEALTHCARE   (Norway)

Author keywords

Integrin v 3; Integrin v 5; Molecular imaging; PET; RGD peptide; Tumor vasculature

Indexed keywords

AH 111585; AH 111585 F 18; FLUORINE 18; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PACLITAXEL; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEWIS CARCINOMA; LOW DRUG DOSE; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; NEOPLASMS; OLIGOPEPTIDES; PACLITAXEL; PEPTIDES; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 58249127731     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.056077     Document Type: Article

References (36)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273-286.
2. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer. 2007;96:1159-1165.
3. Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS. Antiangiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast. 2005;14:466-479.
4. Bradley DP, Tessier JL, Checkley D, et al. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed. 2008;21:42-52.
5. Daldrup-Link HE, Simon GH, Brasch RC. Imaging of tumor angiogenesis: current approaches and future prospects. Curr Pharm Des. 2006;12:2661-2672.
6. McDonald DM, Teicher BA, Stetler-Stevenson W, et al. Report from the Society for Biological Therapy and Vascular Biology faculty of the NCI Workshop on Angiogenesis Monitoring. J Immunother. 2004;27:161-175.
7. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
8. Horton MA. The avb3 integrin "vitronectin receptor." Int J Biochem Cell Biol. 1997;29:721-725.
9. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
10. Eliceiri BP, Cheresh DA. The role of av integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227-1230.
11. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
12. 18F-galacto-RGD PET. J Nucl Med. 2008;49:255-259.
13. 18F-labeled dimeric RGD peptide. Mol Imaging. 2004;3:96-104.
14. Haubner RH, Wester HJ, Weber WA, Schwaiger M. Radiotracer-based strategies to image angiogenesis. Q J Nucl Med. 2003;47:189-199.
15. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999;59:4770-4775.
16. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883-893.
17. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000;60:970-975.
18. Indrevoll B, Kindberg GM, Solbakken M, et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett. 2006;16: 6190-6193.
19. 18F]fluorinated aldehyde-containing prosthetic groups. Bioconjug Chem. 2008;19:951-957.
20. Obenaus A, Smith A. Radiation dose in rodent tissues during micro-CT imaging. J XRay Sci Technol. 2004;12:241-249.
21. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389-4400.
22. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671-680.
23. Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol. 1995;130:1189-1196.
24. 3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging. 2006;33(suppl 1):54-63.
25. 99mTc-labeled cyclic RGD tetramer for noninvasive imaging integrin avb3-positive breast cancer. Bioconjug Chem. 2007;18:438-446.
26. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med. 2006;47:2000-2007.
27. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5(suppl 6):S3-S6.
28. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm. 1999;14:31-36.
29. Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006:259-265, 510-511.
30. Pasqualini R, Koivunen E, Ruoslahti E. av integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15:542-546.
31. 3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
32. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
33. 18F]galacto-RGD. PLoS Med. 2005;2:e70.
34. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
35. Smith NR, James NH, Oakley I, et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther. 2007;6: 2198-2208.
36. 18F-AH111585 in healthy volunteers. J Nucl Med. 2008;49:1664-1667.